Get the Stockscreener App
11.49
1.59%
0.18
Pre-market:
11.41
-0.08
-0.70%
Roivant Sciences Ltd stock is traded at $11.49, with a volume of 2.91M.
It is up +1.59% in the last 24 hours and down -3.61% over the past month.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.
See More
Previous Close:
$11.31
Open:
$11.31
24h Volume:
2.91M
Relative Volume:
0.49
Market Cap:
$8.28B
Revenue:
$158.30M
Net Income/Loss:
$4.74B
P/E Ratio:
-8.5746
EPS:
-1.34
Net Cash Flow:
$-710.11M
1W Performance:
-3.85%
1M Performance:
-3.61%
6M Performance:
+1.06%
1Y Performance:
+30.57%
1-Day Range:
$11.23
$11.51
1-Week Range:
$11.04
$12.01
52-Week Range:
$8.56
$13.05
Roivant Sciences Ltd Stock (ROIV) Company Profile
Name
Roivant Sciences Ltd
Sector
Industry
Phone
441-295-5950
Address
CLARENDON HOUSE, 2 CHURCH STREET, HAMILTON HM11
Compare ROIV with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
| ROIV | 11.49 | 8.28B | 158.30M | 4.74B | -710.11M | -1.34 |
| VRTX | 451.23 | 115.74B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 743.35 | 81.65B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 591.82 | 34.86B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 248.79 | 32.09B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 102.14 | 24.49B | 3.30B | -501.07M | 1.03B | 11.54 |
Roivant Sciences Ltd Stock (ROIV) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-15-24 | Initiated | Wolfe Research | Outperform |
| Jan-05-24 | Initiated | Piper Sandler | Overweight |
| Dec-12-23 | Initiated | Deutsche Bank | Buy |
| Oct-17-23 | Initiated | Guggenheim | Buy |
| Jun-08-23 | Initiated | BofA Securities | Neutral |
| Oct-27-22 | Initiated | JP Morgan | Overweight |
| May-23-22 | Initiated | SVB Leerink | Outperform |
| Apr-29-22 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-15-21 | Initiated | Goldman | Buy |
| Nov-08-21 | Initiated | H.C. Wainwright | Buy |
| Oct-28-21 | Initiated | Citigroup | Buy |
| Oct-26-21 | Initiated | Cowen | Outperform |
| Oct-26-21 | Initiated | Jefferies | Buy |
| Oct-26-21 | Initiated | Truist | Buy |
View All
Roivant Sciences Ltd Stock (ROIV) Latest News
Roivant Sciences' (NASDAQ:ROIV) Shareholders Should Assess Earnings With Caution - Yahoo Finance
Principal Financial Group Inc. Trims Holdings in Roivant Sciences Ltd. (NASDAQ:ROIV) - MarketBeat
Andreas Halvorsen's Recent Transaction in Roivant Sciences Ltd - GuruFocus.com
Roivant Sciences Ltd. (ROIV) Quarterly 10-Q Report - Quartzy
Vivek Ramaswamy: 10 things you ought to know about Trump's DOGE co-lead - MSN
Roivant Sciences Ltd - Reuters.com
Roivant Sciences Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2024 - Marketscreener.com
Roivant Sciences Ltd. (NASDAQ:ROIV) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
Trump’s appointment of Ramaswamy sparks speculation on Korean biotech firms linked to Roivant - KBR
Who is Vivek Ramaswamy? Know about his early life, education, and role as head of the new "Department of Government Efficiency" (DOGE) - MSN
From Vadakkanchery to top US Govt post: Vivek Ramaswamy's Kerala roots - Mathrubhumi English
The Analyst Landscape: 5 Takes On Roivant Sciences - Benzinga
How Vivek Ramaswamy Became A Billionaire - Forbes
Who is Vivek Ramaswamy? What to know about Cincinnati billionaire part of Trump's Cabinet - The Cincinnati Enquirer
Vivek Ramaswamy Net Worth 2024: How He Built a Billion-Dollar Empire - Black Star News
Vivek Ramaswamy's journey from bright son of immigrants to being Donald Trump's pick - The Economic Times
Roivant Sciences Ltd. (NASDAQ:ROIV) Q2 2024 Earnings Call Transcript - Insider Monkey
Vivek Ramaswamy Net Worth 2024: Salary, Net Worth in Rupees (INR), Annual Income, Houses, and Cars. - Jagran Josh
Who Is Vivek Ramaswamy, The Biotech Entrepreneur Now Part Of Trump 2.0 - NDTV
Vivek Ramaswamy Net Worth: How this key Trump aide built his billion-dollar empire - Moneycontrol
Who is Vivek Ramaswamy? Know about his early life, education, and role as head of the new 'Department of - The Times of India
Roivant Sciences Ltd (ROIV) Q2 2024 Earnings Call Highlights: Strong Cash Position and ... By GuruFocus - Investing.com Canada
Vivek Ramaswamy Net Worth: From Transforming 'Ailing' Pharma To Betting On Crypto; How Trump’s Key Aide Built His Empire - Jagran English
FMR LLC Bolsters Stake in Roivant Sciences Ltd - GuruFocus.com
Roivant Sciences Reports Q2 2024 Financial Results - TipRanks
Roivant Sciences earnings missed by $0.02, revenue fell short of estimates - Investing.com Canada
Vivek Ramaswamy's Net Worth: How Harvard-Yale graduate became rich by selling 'sick' pharma companies - The Economic Times
Vivek Ramaswamy Net Worth: How Much Money Does the Co-Director of D.O.G.E Have? - Revista Merca2.0
Roivant Sciences Ltd. (ROIV) Misses Q2 EPS by 2c - StreetInsider.com
Roivant Sciences Ltd. (ROIV) Reports Q2 Loss, Misses Revenue Estimates - Yahoo Finance
Roivant Reports Financial Results for the Second Quarter Ended September 30, 2024, and Provides Business Update - The Manila Times
Roivant Sciences Ltd (ROIV) Q2 2025 Earnings Report Preview: Wha - GuruFocus.com
ROIVWroivw Latest Stock News & Market Updates - StockTitan
Vanguard Group Inc's Strategic Acquisition in Roivant Sciences L - GuruFocus.com
Roivant Sciences (ROIV) to Release Earnings on Tuesday - MarketBeat
Roivant Sciences Ltd. (NASDAQ:ROIV) Shares Acquired by Impax Asset Management Group plc - MarketBeat
Allspring Global Investments Holdings LLC Sells 115,694 Shares of Roivant Sciences Ltd. (NASDAQ:ROIV) - MarketBeat
Roivant to Report Financial Results for the Second Quarter Ended September 30, 2024 and Provide Business Update on Tuesday, November 12, 2024 - Yahoo Finance
Organon Completes Acquisition of Dermavant - njbmagazine.com
China Universal Asset Management Co. Ltd. Boosts Position in Roivant Sciences Ltd. (NASDAQ:ROIV) - MarketBeat
Organon completes Dermavant Sciences acquisition By Investing.com - Investing.com Canada
Organon completes Dermavant Sciences acquisition - Investing.com
Organon Completes Acquisition of Dermavant, including Innovative Dermatologic Therapy, VTAMA® (tapinarof) Cream, 1% - StockTitan
At Roivant Sciences, Eric Venker Chooses To Exercise Options, Resulting In $782K - Benzinga
Options Exercise: Eric Venker At Roivant Sciences Realizes $782K - Benzinga
Roivant Sciences Ltd. (NASDAQ:ROIV) COO Eric Venker Sells 100,000 Shares - MarketBeat
Roivant Sciences president sells $1.17 million in shares By Investing.com - Investing.com Australia
Roivant Sciences president sells $1.17 million in shares - Investing.com
Roivant Sciences: Good Value, But Near-Term Catalysts Could Bring Volatility (ROIV) - Seeking Alpha
Leerink maintains outperform on Roivant with steady target By Investing.com - Investing.com Australia
Roivant Sciences Ltd Stock (ROIV) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.69%
6.90%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):